microbiome-cancer-agent

<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

---

name: 'microbiome-cancer-agent'

description: 'AI-powered analysis of microbiome-cancer interactions including tumor microbiome profiling, immunotherapy response prediction, and microbiome-targeted therapeutic opportunities.'

measurable_outcome: Execute skill workflow successfully with valid output within 15 minutes.

allowed-tools:

• read_file
• run_shell_command

---

Microbiome-Cancer Interaction Agent

The Microbiome-Cancer Interaction Agent analyzes relationships between the microbiome and cancer, including tumor-associated bacteria, gut microbiome effects on immunotherapy, and microbiome-targeted therapeutic strategies.

When to Use This Skill

• When analyzing tumor microbiome composition from sequencing data.
• To predict immunotherapy response based on gut microbiome profiles.
• For identifying microbiome-based biomarkers in cancer.
• When assessing antibiotic impact on cancer treatment efficacy.
• To design microbiome-modulating therapeutic interventions.

Core Capabilities

1. Tumor Microbiome Analysis: Profile intratumoral bacteria from tumor sequencing data.

1. Gut-Cancer Axis: Analyze fecal microbiome associations with cancer outcomes.

1. ICI Response Prediction: Predict checkpoint inhibitor response from microbiome.

1. Metabolite Profiling: Link microbial metabolites to cancer phenotypes.

1. Antibiotic Impact: Model antibiotic effects on treatment efficacy.

1. FMT/Probiotic Design: Support microbiome-modulating interventions.

Microbiome-Cancer Associations

| Cancer Type | Key Bacteria | Association |

|-------------|--------------|-------------|

| Colorectal | Fusobacterium nucleatum | Promotion, poor prognosis |

| Colorectal | Bacteroides fragilis (ETBF) | Carcinogenesis |

| Gastric | Helicobacter pylori | Established carcinogen |

| Pancreatic | Gammaproteobacteria | Drug metabolism |

| Breast | Fusobacterium | Metastasis |

| Oral | Porphyromonas gingivalis | Oral SCC |

Workflow

1. Input: 16S/shotgun metagenomics, tumor sequencing, clinical data.

1. Taxonomy Profiling: Identify bacterial composition at genus/species level.

1. Diversity Analysis: Calculate alpha and beta diversity metrics.

1. Association Testing: Correlate microbiome with outcomes.

1. Functional Prediction: Infer metabolic potential (PICRUSt2, HUMAnN).

1. Prediction Modeling: Build response prediction models.

1. Output: Microbiome profile, associations, predictions, interventions.

Example Usage

User: "Analyze gut microbiome from melanoma patients and predict anti-PD-1 response."

Agent Action:

python3 Skills/Microbiome/Microbiome_Cancer_Agent/microbiome_cancer.py \
    --metagenomics fecal_shotgun.fastq.gz \
    --tumor_data melanoma_rnaseq.tsv \
    --clinical treatment_outcomes.csv \
    --analysis ici_response \
    --reference metaphlan_db \
    --output microbiome_report/

ICI Response and Microbiome

Favorable Microbiome:

• Akkermansia muciniphila
• Faecalibacterium prausnitzii
• Bifidobacterium spp.
• Ruminococcaceae family
• High diversity

Unfavorable Microbiome:

• Bacteroidales (in some studies)
• Low diversity
• Post-antibiotic dysbiosis

Microbial Metabolites in Cancer

| Metabolite | Source | Effect |

|------------|--------|--------|

| Butyrate | Clostridia | Anti-inflammatory, anti-tumor |

| Inosine | Akkermansia | Enhanced ICI response |

| TMAO | Various | Pro-tumorigenic |

| Secondary bile acids | Various | Variable, context-dependent |

| LPS | Gram-negative | Inflammation, mixed effects |

AI/ML Components

Response Prediction:

• Random forest on microbiome features
• Neural networks for metagenomic profiles
• Integration with host factors

Microbiome-Metabolite Linking:

• Genome-scale metabolic models
• Correlation networks
• Causal inference methods

Intervention Design:

• FMT donor selection
• Probiotic consortium optimization
• Antibiotic avoidance recommendations

Tumor Microbiome Analysis

Challenges:

• Low bacterial biomass in tumors
• Contamination from reagents/environment
• Batch effects
• Need for stringent controls

Best Practices:

• Negative controls (extraction, PCR)
• Decontamination algorithms (decontam, SCRuB)
• Multiple validation methods
• Orthogonal confirmation (FISH, culture)

Clinical Implications

1. Biomarker Development: Microbiome-based response prediction
2. Intervention Timing: Avoid antibiotics pre-ICI
3. FMT Trials: Responder microbiome transfer
4. Probiotics: Rationally designed consortia
5. Prebiotics: Fiber to support beneficial bacteria

Prerequisites

• Python 3.10+
• QIIME2, Metaphlan, HUMAnN
• R (phyloseq, vegan)
• ML frameworks

Related Skills

• Metagenomics - For general microbiome analysis
• Immune_Checkpoint_Combination_Agent - For ICI optimization
• Metabolomics - For metabolite analysis

Research Frontiers

1. Intratumoral bacteria: Direct tumor effects
2. Phage therapy: Targeting pathobionts
3. Engineered probiotics: Drug-producing bacteria
4. Diet interventions: Modulating microbiome for therapy

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->